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Background: Epidemiological data of probable cluster headaches (CH) are scarce in the
relevant literature. Here, we sought to assess the prevalence and clinical characteristics
of probable CH in comparison with definite CH.
Methods: Data used in this study were obtained from the Korean Cluster Headache
Registry (KCHR), a prospective, cross-sectional, multicenter headache registry that
collected data from consecutive patients diagnosed with CH.
Results: In total, 159 patients were enrolled in this study; 20 (12.6%) were diagnosed
with probable CH. The most common unfulfilled criterion in patients with probable
CH was the duration of attack, which was found in 40% of patients with probable
CH. Among clinical characteristics, the number of autonomic symptoms tended to be
lower in probable CH than in definite CH (1.7 ± 1.2 vs. 2.4 ± 1.5, p = 0.051) and
conjunctival injection and lacrimation showed an increased odds ratio (OR) [OR = 3.03;
95% confidence interval (CI): 1.03–8.33] in definite CH. The groups did not differ with
regard to baseline demographic characteristics, disability, impact on life, or treatment
response.
Conclusions: Probable CH is relatively common among CH disorders, with a clinical
impact similar to that of definite CH.
Keywords: cluster headache, autonomic symptom, probable diagnosis, definite diagnosis, trigeminal autonomic
cephalalgia
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INTRODUCTION
Cluster headache (CH), which is characterized by severe
headache localized in or around the eye and accompanied by
cranial autonomic symptoms (CAS), is the most painful form
of primary headache disorder. Based on epidemiological surveys
from the USA and Europe, CH has a prevalence of 0.1% in the
general population (1). The diagnosis of CH is determined based
on the presence of a strictly unilateral headache attack lasting 15–
180min and occurring up to eight times a day. Headaches must
be accompanied by at least one autonomic symptom ipsilateral
to the pain, a sense of agitation, or both (2, 3). Episodic CH is the
most common presentation, reported in 85–90% of patients with
CH, with headaches occurring as a series of daily attacks lasting
for weeks or months, followed by complete remission (4).
Probable CH is diagnosed when a patient’s headache fulfills all
but one criterion for CH based on the International Classification
of Headache Disorder (ICHD) (2, 3). Diagnosis of this group
of headache sufferers is an important issue in clinical practice.
Considering the similarity in the clinical characteristics and
treatment response profiles, cases of probable CH may be driven
by the same pathophysiological processes that drive definite CH.
Despite this uncertainty in clinical evaluation, the incorporation
of a probable diagnosis in headache classification may increase
the likelihood that a patient will receive an accurate diagnosis
and adequate treatment at their initial visit (5). If probable CH
were found to be a prevalent form of CH, studies that focused
entirely on definite diagnoses may have underestimated the
significance and impact of probable CH. Probable migraine has
been reported to be a common primary headache disorder with a
prevalence of 4.5–14.6% in Western and Asian countries (5–11).
However, epidemiological data assessing probable diagnoses of
CH or trigeminal autonomic cephalalgia (TAC) remain limited.
Previously, a study found the prevalence of suspected CH in 32
of 1,145 (2.7%) cases included in a community-based survey,
whereas the prevalence of probable TAC among all TAC cases was
40.9% in a multicenter study of first-visit headache outpatients
at neurology clinics (12, 13). Furthermore, neither the clinical
characteristics of probable CH nor its effects on the quality of life
of sufferers have been reported.
Here, we sought to assess the proportion of probable CH
diagnoses and to clarify the diagnostic profile of individuals with
probable CH. In addition, the clinical characteristics of probable
CHpatients were comparedwith those of patients diagnosed with
definite CH.
METHODS
Study Design and Patients
This study was performed using data obtained from the Korean
Cluster Headache Registry (KCHR) study, a multicenter, cross-
sectional headache registry that used prospectively collected data
Abbreviations:CH, Cluster headache; CAS, Cranial Autonomic Symptom; ICHD,
International Classification of Headache Disorder; TAC, Trigeminal Autonomic
Cephalalgia; ICHD-3β, International Classification of Headache Disorder, 3rd
Edition, beta version; HIT-6, Headache Impact Test-6; PHQ-9, Patient Health
Questionnare-9; GAD-7, Generalized Anxiety Dirorder-7; PSS-4, Perceived Stress
Scale-4.
from consecutive patients with CH treated at the neurology
outpatient departments of 15 hospitals in Korea between August
2016 and May 2018. This study was conducted at 13 university
hospitals (8 tertiary referral hospitals and 5 secondary referral
hospitals) and 2 secondary referral general hospitals throughout
Korea in accordance with the Declaration of Helsinki and
good clinical practice. Board-certified neurologists with a special
interest in headache conducted the study, and all investigators
were Directors on the Korean Headache Society Board.
All participants were examined by each investigator to
confirm that the diagnosis fulfilled the criteria set forth in the
International Classification of Headache Disorders, 3rd Edition,
beta version (ICHD-3β) (2) for CH and asked to complete
questionnaires in relation to the visit. Participants who met the
diagnostic criteria for probable or definite CH based on ICHD-3β
were identified at the initial interview, and their diagnoses were
finally confirmed via a re-evaluation process at least 2 weeks later.
The study protocol and informed consent form were reviewed
and approved by the Institutional Review Board of each hospital.
Written informed consent was obtained from all participants
before their enrolment in the study.
Clinical Information and Questionnaire
Investigators assessed the demographic features of and recorded
the clinical information about each patient’s current and
previous bouts of CH. Clinical information regarding the current
headache episode included location, severity, duration, and
frequency of pain, associated symptoms, and duration of bout
period. Previous history of CH included the time since the first
bout of CH, the total frequency of the cluster period, and the
pattern of recurrence.
Each patient completed a self-administered Headache Impact
Test-6 (HIT-6) questionnaire to measure headache-related
impact, the Patient Health Questionnaire-9 (PHQ-9) to assess
depression, the Generalized Anxiety Dirorder-7 (GAD-7) to
assess anxiety, the EQ-5D to measure of health-related quality
of life, and the Short Form Perceived Stress Scale-4 (PSS-4)
to assess psychological stress. The impact of headaches on an
individual’s quality of life, as determined based on HIT-6 scores,
was defined as mild (≤49), some (50–55), substantial (56–59),
and severe (≥60) impact. Cut-off points for depression and
anxiety were defined as PHQ-9 scores ≥8 and GAD-7 scores ≥6,
respectively.
Statistics
For continuous variables, the Kolmogorov–Smirnov test was
used to assess the normality of the distribution. After normality
was confirmed, chi-square and student’s t-tests were used to
compare the nominal and the continuous variables, respectively.
When normality was not confirmed, continuous variables
were analyzed by Mann–Whitney U-tests. We compared the
odds ratios (ORs) and 95% confidence intervals (CIs) for the
characteristics of definite CH with those of probable CH through
univariate regression analyses. All analyses were performed using
the Statistical Packages for the Social Sciences for Windows
ver. 22.0 (IBM, Armonk, NY, USA); P < 0.05 were considered
statistically significant.
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RESULTS
Prevalence and Diagnostic Profiles of
Probable CH
In total, 159 patients, 20 (12.6%) of whom were diagnosed with
probable CH, 114 (71.7%) with episodic CH, 5 (3.1%) with
chronic CH, and 20 (12.6%) with unclassified CH, were enrolled
in this study. Themost commonly unfulfilled criterion in patients
with probable CH was the duration of attack, which was found
in eight (40%) patients with probable CH. The duration of the
attack of probable CH (163.0 ± 164min) tended to be longer
than that of definite CH (94.3 ± 52.9min), but the difference
was not significant (p = 0.078). Specifically, it exceeded 180min
in six of eight patients and was under 15min in two. Other
unmet criteria necessary for a definitive diagnosis of CH included
total attack number (4; 20%), headache frequency (3; 15%),
associated autonomic symptom (2; 10%), pain severity (3; 10%),
and headache location (1; 5%; Figure 1).
Clinical Characteristics of Patients With
Definite and Probable CH
No significant differences in the clinical characteristics of patients
with definite and probable CH were observed, including with
regard to mean age, male to female ratio, body mass index
(BMI), alcohol use, and smoking status. Among the headache
characteristics, patients with probable CH showed a tendency
toward fewer CAS compared to those with definite CH (1.7± 1.2
vs. 2.4 ± 1.5, p = 0.051; Table 1). Among all CAS, conjunctival
injection and lacrimation had an increased OR among those
with definite CH (OR = 3.03; 95% CI: 1.03–8.33; Table 2). The
headache duration of those with probable CH was longer than
that of those with definite CH; however, this difference failed
FIGURE 1 | The reason for failure of definite cluster headache diagnosis.
to reach statistical significance (163.0 ± 164.0 vs. 94.3 ± 52.9,
p= 0.078).
Psychiatric Comorbidity, Impact on Quality
of Life, and Treatment Response in
Patients With Definite and Probable CH
Next, we assessed psychosomatic comorbidities, including
anxiety, depression, and stress using GAD-7, PHQ-9, and PSS-
4 scores, respectively. No significant differences were evident
between patients with definite and probable CH. Similarly, the
headache-related disabilities, as determined based on HIT-6
and EQ-5D scores, of patients with probable and definite CH
(Table 3) were also similar. Oxygen and triptan were the most
commonly reported acute treatments for definite and probable
CH with steroids the most commonly used preventive therapy.
The treatment response to these drugs did not differ between
groups (Table 4).
DISCUSSION
Three major outcomes were observed in this study. First,
the prevalence of probable CH within our patient cohort
was 12.6%, and duration of attack was the most common
unfulfilled criterion differentiating probable and definite
TABLE 1 | Comparison of demographics and clinical features between definite
and probable cluster headache.
Definite CH
(N = 139)
Probable CH
(N = 20)
p
Age (years) 39.1 ± 10.7(19–76) 42.5 ± 12.7(22–80) 0.197
Male sex (%) 117 (84.2%) 17 (85.0%) 1.000
BMI (kg/m2) 24.0 ± 3.4(14–35) 24.7 ± 3.4(20–34) 0.343
Current smoker (%) 65 (44.8%) 7 (35.0%) 0.455
Alcohol drinking (%) 71 (51.1%) 8 (40.0%) 0.492
Age of onset (years) 29.1 ± 13.2(9–78) 30.9 ± 11.7(16–59) 0.549
Total period of cluster
headache (years)
8.7 ± 8.4(0–48) 8.2 ± 7.9(0–24) 0.815
Duration of bout
(weeks)
7.5 ± 10.3(1–57) 5.9 ± 4.7(1–22) 0.329
Total bout number 8.2 ± 12.2(1–100) 9.0 ± 11.5(1–50) 0.778
Presence of seasonal
variation
62 (48.1%) 5 (26.3%) 0.126
Presence of diurnal
variation
71 (52.2%) 8 (40.0%) 0.435
Number of autonomic
symptom
2.4 ± 1.5(0–7) 1.7 ± 1.2(0–4) 0.051
Frequency of headache
(day)
2.2 ± 1.9(0.1–10) 1.8 ± 1.3(0.3–5) 0.336
Duration of headache
(min)
94.3 ± 52.9(12–270) 163.0 ± 164.0(10–600) 0.078
Intensity of headache
(NRS)
9.1 ± 1.1(5–10) 8.6 ± 1.8(4–10) 0.223
The parentheses indicate all range of values. CH, cluster headache.
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TABLE 2 | Univariable odds ratios for definite and probable cluster headache as function of clinical characteristics.
Definite CH (N = 139) Probable CH (N = 20) Univariable OR
P OR (95% CI)
Headache location Orbital, supraorbital, temporal 107 (85.0%) 17 (85.0%) 0.423 1.69 0.53–7.58
Unilaterality 136 (97.8%) 19 (95.0%) 0.461 2.39 0.11–19.14
Headache intensity Severe intensity 128 (92.1%) 17 (85.0%) 0.304 2.05 0.43–7.40
Associated symptoms Conjunctival injection/lacrimation 118 (84.9%) 13 (65.0%) 0.035 3.03 1.03–8.33
Nasal congestion/rhinorrhea 79 (55.8%) 11 (55.0%) 0.877 1.08 0.41–2.77
Eyelid edema 32 (23.0%) 4 (20.0%) 0.763 1.20 0.40–4.40
Forehead and facial sweating 39 (28.1%) 1 (5.0%) 0.055 7.41 1.46–135.38
Forehead and facial flushing 22 (15.8%) 2 (10.0%) 0.500 1.69 0.44–11.12
Ear fullness 13 (9.4%) 1 (5.0%) 0.528 1.96 0.36–36.61
Miosis/ptosis 29 (20.9%) 2 (10.0%) 0.264 2.37 0.63–15.46
Restlessness/agitation 63 (45.3%) 7 (35.0%) 0.387 1.54 0.43–7.40
CH, cluster headache; OR, odds ratios; CI, confidence interval.
TABLE 3 | Psychiatric comorbidity and headache-related disability of individuals
with definite and probable cluster headache.
Definite CH
(N = 139)
Probable CH
(N = 20)
p
GAD-7 scores 7.6 ± 5.5(0–21) 6.1 ± 5.6(0–21) 0.297
Presence of
anxiety (%)
82 (61.2%) 7 (38.9%) 0.121
PHQ-9 scores 7.2 ± 6.0(0–27) 7.9 ± 7.9(0–25) 0.605
Presence of
depression (%)
56 (41.8%) 7 (36.8%) 0.872
PSS-4 scores 6.6 ± 2.8(0–16) 6.0 ± 3.2(0–11) 0.385
EQ-5D scores 0.85 ± 0.14(0.54–0.95) 0.84 ± 0.14(0.55–0.95) 0.640
HIT-6 scores 68.1 ± 7.7(42–78) 63.9 ± 11.2(42–78) 0.117
Presence of
severe impact
112 (83.6%) 13 (65.0%) 0.094
ASC-12 scores 2.5 ± 3.9(0–20) 2.9 ± 4.1(0–16) 0.670
Presence of
cutaneous
allodynia
40 (33.6%) 8 (42.1%) 0.644
The parentheses indicate all range of values. CH, cluster headache; GAD-7, Generalized
Anxiety Dirorder-7; PHQ-9, Patient Health Questionnare-9; PSS-4, Perceived stress Scale
4; HIT-6, Headache Impact Test-6;ASC-12, Allodynia Symptoms Checklist-12.
CH. Second, no differences in demographics characteristics,
disability, or treatment response were observed between
patients with probable and definite CH. Finally, we observed
a tendency toward fewer CAS in patients with probable
CH, whereas the presence of conjunctival injection and
lacrimation was identified as a positive predictor of definite
CH.
A previous multicenter, cross-sectional registry study found
that a diagnosis of probable primary headache disorder, based
on ICHD-3β, was given to 21.3% of first-visit patients due
to incomplete or atypical presentations of the headaches. The
proportions of probable primary headache disorders differed
among the subtypes as follows: migraines (16.1%), tension-type
TABLE 4 | Comparison of treatment response between definite and probable
cluster headache.
Definite CH
(N = 139)
Probable CH
(N = 20)
p
ACUTE TREATMENT
Oxygen 12/14 (85.7%) 1/1 (100.0%) 1.000
NSAIDs 13/55 (23.6%) 5/11 (45.5%) 0.301
Combination analgesics 3/9 (33.3%) 2/4 (50.0%) 1.000
Triptans 83/95 (87.4%) 9/10 (90.0%) 0.476
PREVENTIVE TREATMENT
Steroid 55/62 (88.7%) 8/9 (88.9%) 0.184
Occipital nerve block 13/18 (68.4%) 0/0
Verapamil 69/86 (74.2%) 5/7 (71.4%) 0.743
Lithium 20/30 (66.7%) 2/4(50.0%) 0.471
CH, cluster headache.
headaches (33%), TACs (40.9%), and other primary headache
disorders (14%) (12). Although a difference is noticeable, it is
difficult to make a direct comparison because the number of
patients included and the method of investigation used differed.
In a previous study, the frequency of probable CH, as defined
using the ICHD-II guideline, was similar to that in our study,
with a frequency of 16.5% (14). In our study, the diagnosis
of probable CH was confirmed by re-evaluation at least 2
weeks after the first visit. This research design may help to
strengthen the diagnosis of patients with probable CH. The
previous longitudinal follow-up study investigated the diagnostic
stability of all probable diagnoses using the multicenter headache
registry (15). The initial probable headache diagnosis remained
unchanged in three-quarters of the patients, with a median
follow-up period of 6.5 months. Furthermore, the proportion
of consistently diagnosed probable TAC was similar to that of
other subtypes of probable primary headache disorders. Based on
these results, a diagnosis of probable CH is sufficiently common
among CH patients to warrant further study. Such a study would
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be of importance as little is known about the prevalence and
characteristics of probable CH, which is due, in part to the rarity
of CH as a primary headache syndrome.
According to two population-based surveys, the most
common unmet criterion preventing a definitive migraine
diagnosis was headache duration (61.1 and 82.0%, respectively);
a separate multicenter study identified the number of attacks
(41.9%) and associated symptoms (33%) as the most common
unmet symptoms (6, 10, 12). Number of attacks (65.3%) was also
the most commonly unmet criterion among cases of probable
tension-type headache (12). In terms of unmet criteria, the
prevalence of diagnostic stability was lower in subgroups lacking
data on time-based criteria, such as number of attacks or total
headache period. This lack of data was particularly evident
among migraine and tension type headache patients due to the
fact that a larger proportion of these patients than of other
subgroups of patients progress to a definite diagnosis (15). In
our study, the most common unmet criteria were symptom-
based, which may be related to atypical presentation. Therefore,
the diagnostic stability of probable CH is likely to be confirmed
on follow-up. A better understanding of the characteristics
of the unmet criteria in probable primary headache disorders
would be helpful for differentiating between probable and
definitive diagnoses, allowing for better treatment of headache
patients (16).
Some of the characteristics of patients with probable CH
differed from those with definite CH. Definite CH was
characterized bymore CAS compared to probable CH. According
to the univariate regression analyses, patients with definite CH
showed an increased OR for CAS accompanied by conjunctival
injection and lacrimation. Of the CAS, lacrimation and
conjunctival injection were the most frequent and consistently
reported autonomic features in CH (4, 17–22). Several patients
diagnosed with probable CH without CAS based on ICHD-II
criteria have been included in previous reports, and their clinical
profiles have not significantly differed from those with definite
CH (14, 23). The only distinction between these two populations
was that CH patients without CAS reported less intense attacks
relative to patients with CAS, suggesting that CH without CAS
may represent a milder form of CH (14). CH attacks without CAS
are rare but well known (24, 25), which contradicts the current
hypothesis that activation of the parasympathetic pathway is
required for the generation of a cluster attack. Such findings
suggest that parasympathetic activation is a consequence rather
than the cause of trigeminal activation (26).
CH is frequently associated with psychiatric comorbidities.
Depression, anxiety, and aggressive behavior are among the most
commonly observed psychiatric comorbidities in CH patients
(27, 28). These and other symptoms have a substantial impact
on the patient’s quality of life and, in some cases, can lead to
suicidal ideation due to both the frequency and severity of attacks
(4). Previous cross-sectional prevalence studies, similar to the
one presented here, observed comorbidity rates for depression
ranging from 6.3 to 31.0% in episodic CH and from 11.8 to 43.0%
in chronic CH (29–33). Similarly, anxiety rates ranged from 15.6
to 23.8% in episodic CH and from 11.8 to 75.7% in chronic CH
(29, 30, 32, 33). In our study, the rates of comorbid depression
and anxiety were not significantly different between definite and
probable CH (41.8 vs. 36.8% in depression and 61.2 vs. 38.9%
in anxiety, respectively), with similar mean PHQ-9 and GAD-7
scores, although these rates were higher than those reported in
previous studies.
We also assessed headache-related disability and impact on
quality of life among patients with probable and definite CH.
Previous studies reported disability and reduced quality of life in
probable migraine patients relative to controls, and these rates
were similar to those of migraine sufferers (5–7, 10). Here, the
level of disability and impact on quality of life were comparable
in probable and definite CH.
Like migraine headaches, probable migraines are often sub-
optimally treated, even in those with access to medical care
and prescription drugs (5, 34). Current treatment of probable
migraine is based on the assumption that the pathophysiology
and treatment response profile of probable migraine are similar
to those of migraine (35–38). Cutaneous allodynia, as found
for migraine, suggests that central sensitization may also occur
in CH (39). Both the extent to which the mechanisms of
allodynia are shared across different headache syndromes and
the identity of the specific aspects that may be syndrome-specific
remain unknown. However, a previous study has suggested
that the presence of allodynia not only contributes to our
understanding of the pathophysiological mechanism of CH
but may also be helpful in determining the treatment and
predicting the therapeutic response (40). In our study, there
was no significant difference in the presence of or scores
for cutaneous allodynia between those with probable CH and
those with definite CH. Furthermore, the treatment responses
of the two groups did not differ. As probable CH is a
CH subtype that responds to specific CH therapy, the same
principles of treatment should be applied for both probable and
definite CH.
Recently, the new ICHD-3 criteria were published (3). Among
the more notable changes, such accompanying symptoms as
ipsilateral ear fullness and facial flushing have been excluded
for the diagnosis of CH, as the additional diagnostic value
of these two symptoms was found to be too low (41). Our
study used the ICHD-3β criteria to diagnose CH, which may
represent a limitation of this study. To address this potential
issue, we compared CH patients diagnosed according to the
ICHD-3β criteria with those diagnosed according to the ICHD-
3. Although two patients were reclassified by the ICHD-3, there
was no significant difference in the clinical profiles of patients
diagnosed according to the ICHD-3β and ICHD-3. As this
study used a multicenter, clinic-based design, selection bias was
inevitable. However, considering the rarity of the condition in the
general population, a headache clinic-based study may represent
a reasonable setting for evaluation of the clinical features of
CH. All patients were followed up for at least 2 weeks, and
sufficient data were collected to make a probable diagnosis
of CH. This minimum follow-up period may not have been
sufficient for assessing the diagnostic consequences of probable
CH, and additional long-term follow-up studies will be needed.
Additionally, the subgroup analysis of the response to treatment
might have been significantly underpowered because few patients
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actually received each treatment. Finally, recall bias must be
considered.
In conclusion, probable CH is a prevalent condition among
CH disorders, with a similar disability and impact on quality of
life as definite CH. Therefore, both probable and definite CH,
which have similar clinical characteristics and impact, deserve
similar medical, and therapeutic management.
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